Summary
Lupus nephritis treatment is entering a new phase, shifting from broad immunosuppressants to targeted biologics, with BENLYSTA (belimumab) and GAZYVA (obinutuzumab) emerging as key competitors.
BENLYSTA is the established benchmark, with over a decade of clinical use in SLE and approvals for lupus nephritis since 2020, supported by strong real-world efficacy, safety data, and physician familiarity.
GAZYVA, approved for lupus nephritis in 2025, is a newer entrant backed by positive Phase II/III trial data and FDA Breakthrough Therapy designation, signaling strong clinical potential.
BENLYSTA offers both subcutaneous (at-home) and intravenous (infus...
